Literature DB >> 16235097

Persistent familial hematuria in children and the locus for thin basement membrane nephropathy.

Kesha Rana1, Yan Yan Wang, Harley Powell, Colin Jones, David McCredie, Mark Buzza, Madhara Udawela, Judy Savige.   

Abstract

This study examined how often children with persistent familial hematuria were from families where hematuria segregated with the known genetic locus for the condition known as benign familial hematuria or thin basement membrane nephropathy (TBMN) at COL4A3/COL4A4. Twenty-one unrelated children with persistent familial hematuria as well as their families were studied for segregation of hematuria with haplotypes at the COL4A3/COL4A4 locus for benign familial hematuria and at the COL4A5 locus for X-linked Alport syndrome. Eight families (38%) had hematuria that segregated with COL4A3/COL4A4, and four (19%) had hematuria that segregated with COL4A5. At most, eight of the other nine families could be explained by disease at the COL4A3/COL4A4 locus if de novo mutations, non-penetrant hematuria or coincidental hematuria in unaffected family members was present individually or in combination. This study confirms that persistent familial hematuria is not always linked to COL4A3/COL4A4 (or COL4A5) and suggests the possibility of a further genetic locus for benign familial hematuria. This study also highlights the risk of excluding X-linked Alport syndrome on the basis of the absence of a family history or of kidney failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16235097     DOI: 10.1007/s00467-005-2034-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

1.  Approach to the diagnosis of thin basement membrane nephropathy in females with the use of antibodies to type IV collagen.

Authors:  G Lajoie
Journal:  Arch Pathol Lab Med       Date:  2001-05       Impact factor: 5.534

2.  Two CA-dinucleotide polymorphisms at the COL4A5 (Alport syndrome) gene in Xq22.

Authors:  D F Barker; J Cleverly; P R Fain
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

3.  Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin.

Authors:  F T van der Loop; L A Monnens; C H Schröder; H H Lemmink; M H Breuning; E D Timmer; H J Smeets
Journal:  Kidney Int       Date:  1999-04       Impact factor: 10.612

4.  Familial thin basement membrane nephropathy in children with asymptomatic microhematuria.

Authors:  B Gauthier; H Trachtman; R Frank; E Valderrama
Journal:  Nephron       Date:  1989       Impact factor: 2.847

5.  A comparison of the clinical and laboratory features of thin basement membrane disease (TBMD) and IgA glomerulonephritis (IgA GN).

Authors:  R Auwardt; J Savige; D Wilson
Journal:  Clin Nephrol       Date:  1999-07       Impact factor: 0.975

6.  Benign familial hematuria due to mutation of the type IV collagen alpha4 gene.

Authors:  H H Lemmink; W N Nillesen; T Mochizuki; C H Schröder; H G Brunner; B A van Oost; L A Monnens; H J Smeets
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

7.  Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes (COL4A3 and COL4A4).

Authors:  J A Jefferson; H H Lemmink; A E Hughes; C M Hill; H J Smeets; C C Doherty; A P Maxwell
Journal:  Nephrol Dial Transplant       Date:  1997-08       Impact factor: 5.992

8.  Proteinuria and hematuria in schoolchildren: epidemiology and early natural history.

Authors:  W F Dodge; E F West; E H Smith
Journal:  J Pediatr       Date:  1976-02       Impact factor: 4.406

9.  Microscopic hematuria in school children: epidemiology and clinicopathologic evaluation.

Authors:  V M Vehaskari; J Rapola; O Koskimies; E Savilahti; J Vilska; N Hallman
Journal:  J Pediatr       Date:  1979-11       Impact factor: 4.406

10.  Renal tract abnormalities detected in Australian preschool children.

Authors:  R J Hogg; S Harris; D M Lawrence; P H Henning; N Wigg; K F Jureidini
Journal:  J Paediatr Child Health       Date:  1998-10       Impact factor: 1.954

View more
  6 in total

1.  Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseases.

Authors:  Kesha Rana; Stephen Tonna; Yan Yan Wang; Lydia Sin; Tina Lin; Elizabeth Shaw; Ishanee Mookerjee; Judy Savige
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

2.  Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical?

Authors:  Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

3.  Do mutations in COL4A1 or COL4A2 cause thin basement membrane nephropathy (TBMN)?

Authors:  Ke Wei Zhang; Stephen Tonna; Yan Yan Wang; Kesha Rana; Smitha Padavarat; Judy Savige
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

4.  Discordance between skin biopsy and kidney biopsy in an X-linked carrier of Alport syndrome.

Authors:  Lorraine A Hamiwka; David H George; Silviu Grisaru; Julian P Midgley
Journal:  Pediatr Nephrol       Date:  2007-02-10       Impact factor: 3.714

Review 5.  The renal biopsy in the genomic era.

Authors:  Helen Liapis; Joseph P Gaut
Journal:  Pediatr Nephrol       Date:  2012-11-21       Impact factor: 3.714

6.  Frequency of COL4A3/COL4A4 mutations amongst families segregating glomerular microscopic hematuria and evidence for activation of the unfolded protein response. Focal and segmental glomerulosclerosis is a frequent development during ageing.

Authors:  Louiza Papazachariou; Panayiota Demosthenous; Myrtani Pieri; Gregory Papagregoriou; Isavella Savva; Christoforos Stavrou; Michael Zavros; Yiannis Athanasiou; Kyriakos Ioannou; Charalambos Patsias; Alexia Panagides; Costas Potamitis; Kyproula Demetriou; Marios Prikis; Michael Hadjigavriel; Maria Kkolou; Panayiota Loukaidou; Androulla Pastelli; Aristos Michael; Akis Lazarou; Maria Arsali; Loukas Damianou; Ioanna Goutziamani; Andreas Soloukides; Lakis Yioukas; Avraam Elia; Ioanna Zouvani; Polycarpos Polycarpou; Alkis Pierides; Konstantinos Voskarides; Constantinos Deltas
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.